Month: September 2021

Registration for the September 21, 2021 event now open VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announces that Eric A. Adams, CEO of InMed, and Shane Johnson, Co-Founder of BayMedica Inc. (“BayMedica”) will present at Tribe Public’s Webinar Presentation and Q&A event titled “Accelerating The Commercialization of Rare Cannabinoids”. The event is scheduled to begin at 8.30 am Pacific/11.30 am Eastern on September 21, 2021. To register to join the complimentary, ZOOM webinar-based event, please visit Tribe Public LLC at INM.TribePublic.com. Once registered, participants may begin forwarding their questions for InMed’s & BayMedica’s management to Tribe...

Dallas, Sept. 17, 2021 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv® software, the end-to-end customer experience platform built for growing small businesses and emerging franchises, announced today the dates for Connect21, Thryv’s annual conference designed to bring small business owners together to network, learn and celebrate their entrepreneurial spirit.  The 2-day virtual event, to be held on November 10 and 11, will focus on the latest tips and proven strategies that help small business owners build and grow their businesses in today’s digital environment. From established businesses to aspiring business owners, attendees will take away key insights from the conference’s fast-paced agenda full of lively interactive discussions with top speakers.  “Thryv brought greater value to my business...

Mechelen, Belgium; 17 September 2021; 13.15 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), a once–daily, oral, JAK1 preferential inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Following this positive opinion, a final decision from the European Commission is expected later this year. The CHMP positive opinion is based on data from the pivotal Phase 2b/3 SELECTION program, which evaluated filgotinib as an induction and maintenance therapy in adult patients with moderately...

Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusions If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLCBasel, 17 September 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. “This positive CHMP opinion for Gavreto represents another important step towards our goal of providing effective therapeutics that target genomic...

SLATE version (v) 1, Gritstone’s “off the-shelf” neoantigen immunotherapy (including KRAS, TP53 mutations), elicited multiple molecular responses and an unconfirmed RECIST radiologic response in patients with NSCLC who had progressed on prior immunotherapy SLATE v2 (a mutant KRAS-focused version), which is optimized for increased immune response, has been administered to the first patient in Phase 2 testingEMERYVILLE, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) —  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced results with its SLATE v1 product (“off-the-shelf” shared neoantigen immunotherapy in combination with intravenous nivolumab and subcutaneous ipilimumab) and dosing of the first patient in a Phase...

GRANITE individualized immunotherapy demonstrates objective evidence of efficacy in end-stage colorectal cancer (CRC) patients (3rd line or greater) who have “cold” tumors at baseline44% molecular response rate (4/9) by ctDNA (circulating tumor DNA) analysis Molecular response associated with extended median overall survival >17 monthsPhase 2/3 randomized, controlled trial of maintenance GRANITE immunotherapy in newly diagnosed, metastatic, microsatellite-stable (MSS)-CRC patients expected to start in 1H 2022, has registrational intent and has been discussed with the FDA Randomized, controlled phase 2 trial of adjuvant GRANITE immunotherapy in MSS-CRC patients with stage II/III disease who are ctDNA+ after definitive surgery is expected to start in 1H22Webcast today, September 17 at 1:30pm ET EMERYVILLE, Calif., Sept. 17, 2021...

Barranquilla, Colombia, Sept. 17, 2021 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NASDAQ: TGLS) (“Tecnoglass” or the “Company”), a leading manufacturer of architectural glass, windows, and associated aluminum products serving the global residential and commercial end markets, today announced that the Company will attend the following virtual investor conferences:D.A. Davidson 20th Annual Diversified Industrials & Services Virtual Conference, September 22, 2021 Sidoti Fall Virtual Investor Conference, September 23, 2021The Company will present at the Sidoti Fall Virtual Investor Conference on Thursday, September 23, 2021 at 10:00 a.m. eastern time (9:00 a.m. Bogota, Colombia time). A live broadcast of the presentation, including presentation materials, may be accessed through the Investor Relations section...

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) — BC Craft Supply Co. Ltd., (CSE: CRFT) (“CRFT” or the “Company”), a diversified wellness company advancing cannabinoid and psychedelic innovation and psychotherapy, wishes to announce that it has appointed Anthony Laud as its Chief Financial Officer (“CFO”), effective immediately. Mr. Laud will replace Mr. Matt Watters, whom has acted as interim CFO. Mr. Laud holds a Bachelor of Science (Accounting & Finance) from Birmingham University UK, ACMA from the UK Institute of Chartered Management Accountants (reciprocal agreement with CPA). He has 15+ years’ experience in financial and strategic leadership roles. Currently, Mr. Laud is the principal of AJLaud Financial Consulting Ltd. through which he advises numerous cannabis licensed producers and processers. Mr. Laud...

CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, will present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit being held virtually from September 20th – 23rd. Presentation DetailsDate: Tuesday, September 21st, 2021Time: 8:15 a.m. ETPresenter: Carrie Bourdow, President & CEOWebcast: https://wsw.com/webcast/oppenheimer16/trvn/2838334A link to the webcast will be available on the Events page of the Investors section of the Company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar....

Philadelphia, PA, Sept. 17, 2021 (GLOBE NEWSWIRE) — PHILADELPHIA, PA., September 17, 2021 (GLOBE NEWSWIRE)—VSBLTY Groupe Technologies Corp. (OTCQB: VSBGF) (CSE: VSBY) (Frankfurt 5VS) (“VSBLTY”), a leading software provider of security and retail analytics technology, announced today the addition of Amin Shahidi, a former senior strategy executive with Sensormatic, to the VSBLTY Board of Directors. Shahidi brings more than 25 years of high-impact, leadership, digital transformational consulting and consumer/retail expertise to the fast-growing technology company. Most recently, Shahidi was Vice President Global Strategy, Alliances and M&A for Sensormatic Solutions. In making the announcement, VSBLTY Co-founder & CEO Jay Hutton said Shahidi has long recognized the value of VSBLTY retail analytics and security application....